Histopathological and immunohistochemical features of basal-like carcinomas and matched controls
| Basal-like | Control | Significance | ||
|---|---|---|---|---|
| Ck, cytokeratin; ER, oestrogen receptor; ND, not done (definition criteria); PgR: progesterone receptor. | ||||
| *One basal-like carcinoma and one control were scored as HER2 2+ by immunohistochemical analysis; however, both failed to show HER2 amplification by chromogenic in situ hybridisation (data not shown). Therefore, these cases were considered to be negative for HER2 amplification or overexpression. | ||||
| Pathological variables | ||||
| Tumour size (mm) | Median (range) | 20 (5–68) | 20 (4–60) | p = 0.5 (Mann–Whitney) |
| Vascular invasion | Negative | 23 | 17 | p>0.1 |
| Positive | 26 | 32 | ||
| Tumour markers | ||||
| Ck14 | Positive | 32 | 0 | ND |
| Negative | 17 | 49 | ||
| Ck5/Ck6 | Positive | 32 | 0 | ND |
| Negative | 17 | 49 | ||
| Ck17 | Positive | 31 | 0 | ND |
| Negative | 18 | 49 | ||
| Ck14 and Ck5/Ck6 | Positive | 25 | 0 | ND |
| Negative | 24 | 49 | ||
| Ck14 and Ck17 | Positive | 31 | 0 | ND |
| Negative | 18 | 49 | ||
| Ck5/Ck6 and Ck17 | Positive | 17 | 0 | ND |
| Negative | 32 | 49 | ||
| All Ck | Positive | 15 | 0 | ND |
| Negative | 34 | 49 | ||
| ER status | Negative | 40 | 11 | p<0.0001 |
| Positive | 9 | 38 | ||
| PgR status | Negative | 39 | 14 | p<0.0001 |
| Positive | 10 | 35 | ||
| HER2 status* | Negative | 45 | 34 | p<0.01 |
| Positive | 4 | 15 | ||